In today’s briefing:
- Quiddity CSI 300/500 Dec 24 Results: ~90% Hit Rate; Positive Start for the Trade
- Aster DM and Quality Care India: A Deep Dive into the Merger
- Globus Medical Inc.: An Analysis Of Its International Market Expansion & Other Major Drivers
- Natera Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 &Beyond! – Major Drivers
- China Healthcare Weekly (Dec.1)- 2024 NRDL Result, Expectation Gap for Biotech, Henlius’ Wide Spread
- CSI Medical Service Index Rebalance: Three Changes; Brutal Underperformance Could Reverse
- AstraZeneca PLC: Expansion in Rare Disease & Complement Therapeutics Driving Our Optimism! – Major Drivers
Quiddity CSI 300/500 Dec 24 Results: ~90% Hit Rate; Positive Start for the Trade
- The December 2024 index review results for China’s CSI 300 and CSI 500 indices were announced after market close on Friday 29th November 2024.
- There will be 16 ADDs/DELs for CSI 300 and 50 ADDs/DELs for CSI 500.
- The CSI 300 and CSI 500 index rebal events could trigger US$4.5bn and US$3.8bn in one-way flows respectively.
Aster DM and Quality Care India: A Deep Dive into the Merger
- Aster DM Healthcare Ltd (ASTERDM IN) and Quality Care India are merging to form India’s third-largest hospital chain with over 10,150 beds.
- This merger combines two major players, generating significant scale, diversification, and financial strength. The merged entity will benefit from synergies and plans to expand to over 13,000 beds by FY27.
- The merged entity is expected to be EPS accretive and expected to increase EBITDA by 10-15% through synergies
Globus Medical Inc.: An Analysis Of Its International Market Expansion & Other Major Drivers
- Globus Medical reported robust financial performance in its third quarter of 2024, signaling strong growth and successful integration following its merger with NuVasive.
- The company reported sales of $625.7 million, representing a significant growth of 63% from the previous year.
- This was due in large part to the added contributions from the NuVasive acquisition, reflecting the initial success of the merger.
Natera Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 &Beyond! – Major Drivers
- Natera, Inc. reported a significant quarter for Q3 2024, demonstrating positive developments and some challenges inherent in its operations.
- The company achieved a notable revenue increase, reaching $439.8 million, marking a 64% rise compared to the previous year.
- This growth is largely attributed to robust performance across its testing portfolio, particularly within the oncology sector, where the company performed around 137,000 oncology tests, reflecting a substantial 54% year-over-year increase.
China Healthcare Weekly (Dec.1)- 2024 NRDL Result, Expectation Gap for Biotech, Henlius’ Wide Spread
- 2024 NRDL negotiation results were released. Some eye-catching drugs were included this time, which will bring challenges to companies such as Innovent, RemeGen, Gan & Lee Pharmaceuticals, Haisco Pharmaceutical, etc..
- There have been a big “expectation gap” for biotech companies in Hong Kong stock market – It’s a mismatch between what the market thinks and what’s actually happening.
- The progress of Henlius’ privatization is still slower-than-expected. We also do not know how this privatization ranks in terms of strategic significance of capital operations within Fosun Pharma’s system.
CSI Medical Service Index Rebalance: Three Changes; Brutal Underperformance Could Reverse
- CSI announced the changes for the December rebalance after market close on 29 November and the changes will be effective after the close of trading on 13 December.
- There are 3 changes for the index and we estimate passive buying of 0.7-1.4x ADV in the adds and selling of between 0.2-1x ADV in the deletes.
- Trade performance has been horrible as the adds have moved sideways over the last two months and the deletes have skyrocketed – that could change in the next two weeks.
AstraZeneca PLC: Expansion in Rare Disease & Complement Therapeutics Driving Our Optimism! – Major Drivers
- AstraZeneca’s recent earnings outlined promising developments but also noted potential areas for concern.
- The company’s total revenue saw a significant increase of 21% in Q3, driven by strong global demand for its medicines, resulting in a core EPS rise of 27%.
- Year-to-date, total revenue and core EPS have increased by 19% and 11%, respectively.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
